[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the company's financial statements, notes, and management's analysis of its financial condition and operations [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company presents its unaudited consolidated financial statements for the period ended December 31, 2023, including balance sheets, income statements, and cash flows Consolidated Balance Sheet Highlights (Unaudited) | Account | Dec 31, 2023 | Mar 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $80,085 | $475,314 | | Total Current Assets | $1,492,884 | $1,423,980 | | Total Assets | $3,629,802 | $2,438,952 | | **Liabilities & Equity** | | | | Total Current Liabilities | $1,662,120 | $1,453,680 | | Total Liabilities | $2,734,702 | $1,713,927 | | Total Stockholders' Equity | $895,100 | $725,025 | Consolidated Statements of Operations Highlights (Unaudited) | Metric | Three Months Ended Dec 31, 2023 | Nine Months Ended Dec 31, 2023 | | :--- | :--- | :--- | | Revenues | $595,891 | $920,440 | | Gross Profit | $412,804 | $514,170 | | Operating Loss | $(2,133,624) | $(7,971,544) | | Net Loss | $(1,749,848) | $(8,304,578) | | Net Loss Per Share | $(0.12) | $(0.64) | Consolidated Statements of Cash Flows Highlights (Unaudited, Nine Months Ended Dec 31) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | $(5,895,484) | $(5,500,247) | | Net Cash Used in Investing Activities | $(279,802) | $(293,851) | | Net Cash Provided by Financing Activities | $5,780,057 | $61,804 | | **Net Decrease in Cash** | **$(395,229)** | **$(5,732,294)** | [Note 1: Summary of Significant Accounting Policies and Organization](index=9&type=section&id=NOTE%201%20-%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES%20AND%20ORGANIZATION) The company commercializes medical devices and biomaterials for animals, with revenue primarily from product sales to distributors - The company's primary business is the commercialization of its lead product, Spryng™, for treating joint afflictions in dogs and horses[25](index=25&type=chunk) - A significant portion of revenue comes from distribution agreements, with MWI accounting for **65%** and Covetrus for **12%** of total revenues for the nine months ended Dec 31, 2023[47](index=47&type=chunk)[49](index=49&type=chunk) [Note 9: Commitments and Contingencies](index=16&type=section&id=NOTE%209%20%E2%80%93%20COMMITMENTS%20AND%20CONTINGENCIES) The company has operating lease obligations and recently settled a legal dispute with a former employee - As of December 31, 2023, the company has operating lease liabilities with total undiscounted cash flows amounting to **$1,381,592**[82](index=82&type=chunk) - A legal matter with a former employee was settled for **$180,000**, with the expense recorded in September 2023 and paid in October 2023[84](index=84&type=chunk)[85](index=85&type=chunk) [Note 10: Going Concern](index=17&type=section&id=NOTE%2010%20%E2%80%93%20GOING%20CONCERN) Significant net losses and negative cash flow raise substantial doubt about the company's ability to continue operations - The company incurred a net loss of **$8.3 million** for the nine months ended Dec 31, 2023, and had an accumulated deficit of **$80.1 million**[87](index=87&type=chunk) - These conditions raise substantial doubt about the company's ability to continue as a going concern, which is dependent on raising additional capital or achieving profitability[87](index=87&type=chunk)[88](index=88&type=chunk) [Note 11: Stockholders' Equity](index=18&type=section&id=NOTE%2011%20%E2%80%93%20STOCKHOLDERS%27%20EQUITY) The company details equity activities, including convertible debenture conversions and capital raises through stock and warrant sales - In July 2023, the company issued **$550,000** in convertible debentures, which were converted in August 2023 into **385,000 shares** of common stock and warrants to purchase **385,000 shares**[95](index=95&type=chunk)[96](index=96&type=chunk) - The conversion of debentures resulted in a recognized loss on extinguishment of debt of **$534,366**[97](index=97&type=chunk) - The company raised net proceeds of **$1.78 million** in August 2023 and **$317,000** in December 2023 through sales of common stock and warrants[98](index=98&type=chunk)[99](index=99&type=chunk) [Note 12: Subsequent Events](index=24&type=section&id=NOTE%2012%20%E2%80%93%20SUBSEQUENT%20EVENTS) Subsequent to the quarter, the company raised $1.248 million through the sale of common stock and warrants - On February 2, 2024, the company raised **$1,248,000** by selling **1,386,469 units**, each comprising one share and one warrant[117](index=117&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the commercialization of Spryng™, financial results, and the need for additional capital to fund operations [Current Business Operations](index=25&type=section&id=CURRENT%20BUSINESS%20OPERATIONS) The company focuses on commercializing Spryng™ for animal joint afflictions, supported by distribution agreements and clinical studies - The company's lead product, Spryng™, treats joint afflictions in dogs and horses and is protected by a portfolio of **twenty-two patents**[118](index=118&type=chunk) - In December 2023, the distribution agreement with MWI was changed from exclusive to non-exclusive, and a new non-exclusive distribution agreement was signed with Covetrus North America[129](index=129&type=chunk) - The company is conducting multiple clinical studies with Colorado State University and Ethos Veterinary Health to support product adoption and expand distribution channels, with expected completions in 2024[130](index=130&type=chunk) [Results of Operations](index=27&type=section&id=RESULTS%20OF%20OPERATIONS) Revenues increased for both the three and nine-month periods, but operating loss widened due to increased commercialization expenses Comparison of Results for the Three Months Ended December 31 | Metric | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | Revenues | $595,891 | $510,109 | +16.8% | | Gross Profit | $412,804 | $286,422 | +44.1% | | Operating Loss | $(2,133,624) | $(2,318,818) | -8.0% | | Net Loss | $(1,749,848) | $(2,311,618) | -24.3% | Comparison of Results for the Nine Months Ended December 31 | Metric | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | Revenues | $920,440 | $791,563 | +16.3% | | Gross Profit | $514,170 | $366,697 | +40.2% | | Operating Loss | $(7,971,544) | $(6,404,479) | +24.5% | | Net Loss | $(8,304,578) | $(6,388,635) | +30.0% | [Liquidity and Capital Resources](index=29&type=section&id=LIQUIDITY%20AND%20CAPITAL%20RESOURCES) The company faces a working capital deficit and relies on future capital raises to fund ongoing operations and address going concern risk - The company had a working capital deficit of **$169,236** as of December 31, 2023[151](index=151&type=chunk) - Net cash used in operating activities for the nine months ended Dec 31, 2023, was **$5.9 million**, primarily due to the net loss[153](index=153&type=chunk) - Management believes existing cash, supplemented by a February 2024 financing, is sufficient for at least the next two months, but acknowledges the need to raise more capital[152](index=152&type=chunk)[161](index=161&type=chunk) [Qualitative and Quantitative Disclosures About Market Risk](index=30&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) This disclosure is not required as the company qualifies as a smaller reporting company - As a smaller reporting company, PetVivo Holdings, Inc. is not required to provide this information[166](index=166&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of the end of the period - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of December 31, 2023[168](index=168&type=chunk) - There were no significant changes in internal control over financial reporting during the quarter[169](index=169&type=chunk) [PART II. OTHER INFORMATION](index=31&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, and other regulatory disclosures [Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) The company may be involved in ordinary course legal proceedings and refers to Note 9 for a specific settled dispute - The company settled a legal dispute with a former employee, as detailed in Note 9 of the financial statements[171](index=171&type=chunk)[84](index=84&type=chunk) [Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) A significant new risk factor involves a Nasdaq delisting notice for failing to meet stockholders' equity requirements - The company received a delisting notice from Nasdaq on November 17, 2023, for not meeting the minimum stockholders' equity requirement of **$2.5 million**[173](index=173&type=chunk) - An appeal hearing was set for February 13, 2024, and a potential delisting could impair the stock's liquidity and the company's ability to raise capital[173](index=173&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company engaged in several unregistered sales of common stock and warrants to investors and issued equity for services - In October and December 2023, the company sold a total of **477,224 shares** of common stock and issued warrants to investors for proceeds totaling **$517,000**[174](index=174&type=chunk) - The company issued an aggregate of **50,004 shares** of restricted common stock to a consultant for services rendered from October to December 2023[175](index=175&type=chunk) - In December 2023, options to purchase **195,700 shares** were granted to the Board of Directors as compensation[176](index=176&type=chunk) [Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[179](index=179&type=chunk) [Mine Safety Disclosure](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This disclosure is not required for the company - Not required[180](index=180&type=chunk) [Other Information](index=32&type=section&id=Item%205.%20Other%20information) The company reported no other information for this item - None[181](index=181&type=chunk) [Exhibits](index=33&type=section&id=Item%206.%20Exhibits) The report includes key exhibits such as new and amended distribution agreements and required certifications - Key exhibits filed include a new Distribution Agreement with Covetrus North America and a First Amendment to the Distribution Services Agreement with MWI Veterinary Supply Company[183](index=183&type=chunk)

PetVivo Holdings, Inc. (OTC:PETV) Q2 2024 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer & General Counsel John Lai - Chief Executive Officer & President Bob Folkes - Chief Financial Officer Conference Call Participants Operator Welcome, everyone, to the PetVivo Holdings, Inc., 2024 Fiscal Year Second Quarter Earnings Report. This is November 14, 2023, and I will now hand over to Mr. John Dolan to start the call. John Dolan Thank yo ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The unaudited consolidated financial statements show cash decreased to **$55 thousand**, total assets rose to **$4.1 million**, and net losses widened to **$3.7 million** for Q3 and **$6.6 million** for the six-month period [Consolidated Balance Sheets](index=5&type=section&id=CONSOLIDATED%20BALANCE%20SHEETS) As of September 30, 2023, total assets increased to **$4.06 million**, total liabilities rose to **$3.07 million**, and stockholders' equity reached **$989 thousand** Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Item | September 30, 2023 ($) | March 31, 2023 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | 55,254 | 475,314 | | Total Current Assets | 2,015,826 | 1,423,980 | | Total Assets | 4,061,737 | 2,438,952 | | Total Current Liabilities | 1,915,309 | 1,453,680 | | Total Liabilities | 3,073,058 | 1,713,927 | | Total Stockholders' Equity | 988,679 | 725,025 | [Consolidated Statements of Operations](index=6&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Revenues for Q3 2023 were **$207 thousand** with a net loss of **$3.66 million**, while six-month revenues were **$325 thousand** with a **$6.55 million** net loss Statement of Operations Summary (Unaudited) | Metric | Three Months Ended Sep 30, 2023 ($) | Three Months Ended Sep 30, 2022 ($) | Six Months Ended Sep 30, 2023 ($) | Six Months Ended Sep 30, 2022 ($) | | :--- | :--- | :--- | :--- | :--- | | Revenues | 207,366 | 223,280 | 324,549 | 281,454 | | Gross Profit | 66,453 | 75,121 | 101,367 | 80,275 | | Operating Loss | (2,944,343) | (2,119,568) | (5,837,920) | (4,085,661) | | Net Loss | (3,661,153) | (2,111,589) | (6,554,730) | (4,077,017) | | Net Loss Per Share | (0.28) | (0.21) | (0.53) | (0.41) | [Consolidated Statements of Cash Flows](index=8&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Net cash used in operating activities was **$4.6 million** for the six months ended September 30, 2023, offset by **$4.28 million** from financing activities, resulting in a **$420 thousand** cash decrease Cash Flow Summary for the Six Months Ended September 30 (Unaudited) | Cash Flow Activity | 2023 ($) | 2022 ($) | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | (4,604,962) | (3,749,581) | | Net Cash Used in Investing Activities | (93,618) | (83,566) | | Net Cash Provided by Financing Activities | 4,278,520 | 63,413 | | Net Decrease in Cash | (420,060) | (3,769,734) | | Cash at End of Period | 55,254 | 2,337,093 | [Notes to Financial Statements](index=9&type=section&id=Condensed%20Notes%20to%20Financial%20Statements) Notes detail accounting policies, Spryng™ product commercialization, revenue concentration, substantial doubt about going concern, equity issuances, and a legal settlement - The company's lead product is **Spryng™ with OsteoCushion™ Technology**, an intraarticular injection for managing lameness in dogs and horses, which began commercialization in September 2021[23](index=23&type=chunk) - Revenue from the distribution agreement with MWI Veterinary Supply Co. accounted for **69% of total revenues** for the three months ended September 30, 2023[44](index=44&type=chunk) - The company settled a legal dispute with former employee David Masters for **$180 thousand** in September 2023, which was recorded as a settlement expense[84](index=84&type=chunk) - Due to recurring net losses (**$6.6 million** for the six months ended Sep 30, 2023) and negative operating cash flow (**$4.6 million**), there is substantial doubt about the Company's ability to continue as a going concern[86](index=86&type=chunk) - In July 2023, the company issued **$550 thousand** in convertible debentures, which were subsequently converted into **385,000 shares** of common stock and **385,000 warrants** in August 2023, resulting in a loss on extinguishment of debt of **$534 thousand**[95](index=95&type=chunk)[96](index=96&type=chunk)[97](index=97&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Spryng™ commercialization, mixed revenue, increased operating expenses, and critical liquidity concerns, emphasizing the need for additional capital and the 'going concern' issue - The company is focused on the commercialization of its lead product, **Spryng™**, an injectable medical device for managing lameness and osteoarthritis in dogs and horses[113](index=113&type=chunk) - The company is conducting clinical studies with Colorado State University and Ethos Veterinary Health to support the distribution and adoption of **Spryng™**, with expected completion dates in 2024[123](index=123&type=chunk) - The company has a distribution agreement with **MWI Veterinary Supply Co.** which is a key part of its commercialization strategy for **Spryng™** in the United States[121](index=121&type=chunk)[122](index=122&type=chunk) - The company's financial statements include a **'going concern' paragraph**, indicating substantial doubt about its ability to continue operations without raising additional capital[155](index=155&type=chunk)[156](index=156&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Revenues showed mixed results, decreasing in Q3 but increasing over six months, while net losses significantly widened due to increased operating expenses and one-time charges Comparison of Results for the Three Months Ended September 30 | Metric | 2023 ($) | 2022 ($) | Change | | :--- | :--- | :--- | :--- | | Total Revenues | 207,366 | 223,280 | -7.1% | | Operating Expenses | 3,010,796 | 2,194,689 | +37.2% | | Operating Loss | (2,944,343) | (2,119,568) | +38.9% | | Net Loss | (3,661,153) | (2,111,589) | +73.4% | Comparison of Results for the Six Months Ended September 30 | Metric | 2023 ($) | 2022 ($) | Change | | :--- | :--- | :--- | :--- | | Total Revenues | 324,549 | 281,454 | +15.3% | | Operating Expenses | 5,939,287 | 4,165,936 | +42.6% | | Operating Loss | (5,837,920) | (4,085,661) | +42.9% | | Net Loss | (6,554,730) | (4,077,017) | +60.8% | - The increase in operating expenses was primarily due to higher costs for sales and marketing, general and administrative functions (including compensation, legal, and consulting fees), and R&D related to clinical studies for the **Spryng™** product launch[132](index=132&type=chunk)[133](index=133&type=chunk)[134](index=134&type=chunk) - Other expense of **$717 thousand** in Q3 2023 was driven by a **$534 thousand** loss on extinguishment of debt and a **$180 thousand** legal settlement payment[136](index=136&type=chunk)[84](index=84&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces precarious liquidity with **$55 thousand** cash and **$101 thousand** working capital, requiring significant additional capital to sustain operations Liquidity Position as of September 30, 2023 | Metric | Amount ($) | | :--- | :--- | | Cash and cash equivalents | 55,254 | | Current Assets | 2,015,826 | | Current Liabilities | 1,915,309 | | Working Capital | 100,517 | - The company used **$4.6 million** in cash for operating activities during the six months ended September 30, 2023, primarily due to its net loss[148](index=148&type=chunk) - Management believes existing cash, supplemented by **$1.07 million** raised post-quarter end, will only fund operations for the next two months, necessitating further capital raises[147](index=147&type=chunk) [Qualitative and Quantitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) This disclosure is not required for the company as a smaller reporting entity - As a smaller reporting company, PetVivo Holdings, Inc. is not required to provide this disclosure[161](index=161&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were deemed effective by management, with no significant changes to internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of September 30, 2023[162](index=162&type=chunk) - No significant changes were made to the internal control over financial reporting during the second quarter of fiscal year 2024[163](index=163&type=chunk) [PART II. OTHER INFORMATION](index=31&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=31&type=section&id=Item%201.%20Legal%20Proceedings) A legal dispute with a former employee regarding compensation claims was resolved through a mediated settlement for **$180 thousand** - A dispute with former employee David Masters over claims for over **$2 million** in compensation was resolved via a mediated settlement[83](index=83&type=chunk) - In September 2023, the company executed the final agreement and recorded a settlement expense of **$180 thousand**, which was paid in October 2023[84](index=84&type=chunk) [Risk Factors](index=31&type=section&id=Item%201A.%20Risk%20Factors) The company faces a significant risk of Nasdaq delisting due to failing to meet the **$2.5 million** minimum stockholders' equity requirement - The company is at risk of being delisted from the Nasdaq Capital Market for failing to meet the minimum stockholders' equity requirement of **$2.5 million**[167](index=167&type=chunk) - As of September 30, 2023, the company's stockholders' equity was below the required threshold, and it may receive a delisting notice from Nasdaq[167](index=167&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued various unregistered equity securities during the quarter, including common stock to consultants, the CEO, and service providers, and shares from cashless warrant exercises - Issued an aggregate of **49,998 shares** of restricted common stock to a consultant for services rendered in July, August, and September 2023[168](index=168&type=chunk) - Issued **20,200 shares** of restricted common stock to its CEO in lieu of cash compensation for July and August 2023[169](index=169&type=chunk) - Issued **299,500 shares** to various service providers for consulting services valued at **$641 thousand**[171](index=171&type=chunk) - Issued a total of **34,678 shares** of common stock pursuant to cashless exercises of warrants[171](index=171&type=chunk)[172](index=172&type=chunk) [Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[174](index=174&type=chunk) [Mine Safety Disclosure](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This section is not required for the company - Not required[175](index=175&type=chunk) [Other information](index=32&type=section&id=Item%205.%20Other%20information) The company reported no other information for this period - None[176](index=176&type=chunk) [Exhibits](index=33&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the quarterly report, including an ATM Sales Agreement, a Confidential Settlement and Mutual Release Agreement, and various certifications

PetVivo Holdings, Inc. (OTC:PETV) Q1 2024 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer & General Counsel John Lai - CEO, President, & Director Bob Folkes - CFO Conference Call Participants Operator All right. Welcome, everyone, to the PetVivo Holdings, Inc., 2024 Fiscal Year First Quarter Earnings Report. We will now hand over to John Dolan and take it from there. Thank you. John Dolan Thank you, operator. Greetings, and welcome to ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40715 PetVivo Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0363559 (State or other ...

Financial Data and Key Metrics Changes - For the nine months ended December 31, 2022, the company reported revenues of $792,000 compared to $60,000 in the prior year period, driven by $575,000 from shipments of Spryng to MWI [2] - For the third quarter of fiscal 2023, revenues were $510,000 compared to $51,000 in the same quarter of fiscal 2022, with $457,000 from shipments of Spryng to MWI [80][81] - As of December 31, 2022, the company had $375,000 in cash and working capital of $171,000 [2] Business Line Data and Key Metrics Changes - The significant revenue increase is attributed to the exclusive distribution partnership with MWI Animal Health, which began in June 2022 [80] - The company plans to move all production to a new facility starting August 2023, which will enhance manufacturing capacity [82] Market Data and Key Metrics Changes - The market for osteoarthritis (OA) and lameness treatment in the United States is estimated to exceed $4.8 billion annually [102] - The company is seeing good adoption rates among veterinary doctors, with positive feedback from initial product trials [77] Company Strategy and Development Direction - The company aims to generate clinical evidence to support the equine and small animal markets, with several studies expected to conclude and be published in fiscal 2023 [83] - The focus is on expanding sales and marketing efforts, clinical studies, and manufacturing capacity to increase vet acceptance and sales of Spryng [82][95] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the relationship with MWI and the positive reception of Spryng at veterinary conferences, indicating a growing awareness and acceptance of the product [90][84] - The company anticipates that clinical study results will begin to be publicly disclosed in March 2023, which is expected to further support sales efforts [97] Other Important Information - The company raised approximately $1.4 million in January 2023 through a direct offering, which will support ongoing operations and expansion [92] - The company is working with renowned research organizations for clinical trials, enhancing credibility and potential market penetration [108] Q&A Session Summary Question: What is the size of the markets in terms of the number of animals? - The U.S. has approximately 64 million dogs, 53 million cats, and 8 to 14 million horses, with the majority of current revenues coming from the equine market due to more frequent veterinary visits [110] Question: What is the burn rate and upcoming milestones? - The burn rate is around $2 million per quarter, with multiple clinical studies expected to yield results that will aid in product adoption [37] Question: What prompted the expansion into another facility? - The new facility will allow for greater efficiency and scalability, supporting future growth without disrupting current production [124]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterl ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants John Dolan – Chief Business Development Officer and General Counsel John Lai – President and Chief Executive Officer Bob Folkes – Chief Financial Officer Conference Call Participants John Dolan All right. Let us begin the conference. Greetings and welcome to the PetVivo Holdings Second Quarter Fiscal Year 2023 Financial Results Conference Call. I am John Dolan, the Chief Business Developmen ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2023 Results Conference Call August 11, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Dolan Greetings, everyone. And welcome to the PetVivo Holdings First Quarter of Fiscal 2023 Financial Results Conference Call. I am John Dolan, the Chief Busin ...